ME Therapeutics announces initiation of testing of first mRNA formulations from NanoVation Therapeutics collaboration

Vancouver, British Columbia–(Newsfile Corp. – September 18, 2024) – ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) (“ME Therapeutics” or the “Company”), a preclinical-stage biotechnology company developing novel cancer medicines in the field of immuno-oncology, is pleased to announce the initiation of efficacy testing of the first two mRNA formulations from its strategic collaboration with NanoVation Therapeutics Inc. (“NanoVation Therapeutics”).

As previously announced, ME Therapeutics aims to improve the precision and efficacy of myeloid cell-delivered mRNA therapies in vivo to develop potential novel cancer therapies by leveraging NanoVation Therapeutics’ advanced lipid nanoparticle (LNP) technologies. NanoVation Therapeutics’ next-generation lipid nanoparticle platforms enable the efficient delivery of nucleic acids to various tissues. To efficiently target immune cells, NanoVation Therapeutics has rationally designed and further optimized its long-circulating LNP (lcLNP™) technology. NanoVation Therapeutics has initiated numerous programs across multiple RNA modalities.